Literature DB >> 32832863

Understanding How Phosphorylation and Redox Modifications Regulate Cardiac Ryanodine Receptor Type 2 Activity to Produce an Arrhythmogenic Phenotype in Advanced Heart Failure.

Alexander Dashwood1,2,3, Elizabeth Cheesman2, Nicole Beard4,5, Haris Haqqani1,2, Yee Weng Wong1,2, Peter Molenaar2,4.   

Abstract

Heart failure (HF) is a global pandemic with significant mortality and morbidity. Despite current medications, 50% of individuals die within 5 years of diagnosis. Of these deaths, 30-50% will be a result of sudden cardiac death from ventricular arrhythmias. This review discusses two stress-induced mechanisms, phosphorylation from chronic β-adrenoceptor (β-AR) stimulation and thiol modifications from oxidative stress, and how they modulate the cardiac ryanodine receptor type 2 (RyR2) and foster an arrhythmogenic phenotype. Calcium (Ca2+) is the ubiquitous secondary messenger of excitation-contraction coupling and provides a common pathway for contractile dysfunction and arrhythmia genesis. In a healthy heart, Ca2+ is released from the sarcoplasmic reticulum (SR) by RyR2. The open probability of RyR2 is under the dynamic influence of co-proteins, ions, and kinases that are in strict balance to ensure normal physiological functioning. In HF, chronic β-AR activity and production of reactive oxygen species and reactive nitrogen species provide two stress-induced mechanisms uncoupling RyR2 control, resulting in pathological diastolic SR Ca2+ leak. This increased cytosolic [Ca2+] promotes Ca2+ extrusion via the local Na+/Ca2+ exchanger, resulting in net sarcolemmal depolarization, delayed after depolarization and ventricular arrhythmia. Experimental models researching oxidative stress and phosphorylation have aimed to identify how post-translational modifications to the RyR2 macromolecular complex, and the associated Na+/Ca2+ cycling proteins, result in pathological Ca2+ handling and diastolic leak. However, the causative molecular changes remain controversial and undefined. Through understanding the molecular mechanisms that produce an arrhythmic phenotype, novel therapeutic targets to treat HF and prevent its malignant course can be identified.
Copyright © 2020 American Chemical Society.

Entities:  

Year:  2020        PMID: 32832863      PMCID: PMC7432681          DOI: 10.1021/acsptsci.0c00003

Source DB:  PubMed          Journal:  ACS Pharmacol Transl Sci        ISSN: 2575-9108


  131 in total

1.  Differential modulation of L-type Ca2+ current by SR Ca2+ release at the T-tubules and surface membrane of rat ventricular myocytes.

Authors:  Fabien Brette; Laurent Sallé; Clive H Orchard
Journal:  Circ Res       Date:  2004-06-10       Impact factor: 17.367

2.  Characterization and autoradiographic localization of beta-adrenoceptor subtypes in human cardiac tissues.

Authors:  B F Buxton; C R Jones; P Molenaar; R J Summers
Journal:  Br J Pharmacol       Date:  1987-10       Impact factor: 8.739

3.  Phenytoin: an old but effective antiarrhythmic agent for the suppression of ventricular tachycardia.

Authors:  Louis W Wang; Rajesh N Subbiah; Michael J Kilborn; Richard F Dunn
Journal:  Med J Aust       Date:  2013-08-05       Impact factor: 7.738

Review 4.  Calcium Signaling and Cardiac Arrhythmias.

Authors:  Andrew P Landstrom; Dobromir Dobrev; Xander H T Wehrens
Journal:  Circ Res       Date:  2017-06-09       Impact factor: 17.367

5.  Cysteine-3635 is responsible for skeletal muscle ryanodine receptor modulation by NO.

Authors:  J Sun; C Xin; J P Eu; J S Stamler; G Meissner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-18       Impact factor: 11.205

6.  Functional beta3-adrenoceptor in the human heart.

Authors:  C Gauthier; G Tavernier; F Charpentier; D Langin; H Le Marec
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

7.  Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure.

Authors:  Lars Køber; Jens J Thune; Jens C Nielsen; Jens Haarbo; Lars Videbæk; Eva Korup; Gunnar Jensen; Per Hildebrandt; Flemming H Steffensen; Niels E Bruun; Hans Eiskjær; Axel Brandes; Anna M Thøgersen; Finn Gustafsson; Kenneth Egstrup; Regitze Videbæk; Christian Hassager; Jesper H Svendsen; Dan E Høfsten; Christian Torp-Pedersen; Steen Pehrson
Journal:  N Engl J Med       Date:  2016-08-27       Impact factor: 91.245

8.  Adrenergic regulation of cardiac contractility does not involve phosphorylation of the cardiac ryanodine receptor at serine 2808.

Authors:  Scott M MacDonnell; Gerardo García-Rivas; Joseph A Scherman; Hajime Kubo; Xiongwen Chen; Héctor Valdivia; Steven R Houser
Journal:  Circ Res       Date:  2008-04-03       Impact factor: 17.367

Review 9.  The low-affinity site of the beta1-adrenoceptor and its relevance to cardiovascular pharmacology.

Authors:  Alberto J Kaumann; Peter Molenaar
Journal:  Pharmacol Ther       Date:  2008-04-11       Impact factor: 12.310

10.  Gαi is required for carvedilol-induced β1 adrenergic receptor β-arrestin biased signaling.

Authors:  Jialu Wang; Kenji Hanada; Dean P Staus; Michael A Makara; Giri Raj Dahal; Qiang Chen; Andrea Ahles; Stefan Engelhardt; Howard A Rockman
Journal:  Nat Commun       Date:  2017-11-22       Impact factor: 14.919

View more
  1 in total

Review 1.  The function and regulation of calsequestrin-2: implications in calcium-mediated arrhythmias.

Authors:  Elliot T Sibbles; Helen M M Waddell; Valeria Mereacre; Peter P Jones; Michelle L Munro
Journal:  Biophys Rev       Date:  2022-01-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.